

**To customers of the
Dräger ventilators
Infinity Acute Care System - Workstation Critical Care (Evita V500),
Infinity Acute Care System – Workstation Neonatal Care (Babylog VN500)
and Evita V300**

August 2021

Important Safety Notice!

Occasional restarts of the device

Only the following products are affected:

Infinity Acute Care System - Workstation Critical Care (Evita V500) with SW2.60 and lower with installed CO2 measurement option.

Infinity Acute Care System – Workstation Neonatal Care (Babylog VN500) with SW2.60 and lower with installed CO2 measurement option.

Evita V300 with SW2.60 and lower with installed CO2 measurement option.

Dear Madam or Sir,

In the course of our global market surveillance activities, we have become aware of sporadic cases in which the above-mentioned products restarted.

A restart is a designed system recovery function to restore the proper function of the ventilator. In the rare reported cases, however, an error in the data processing of the activated CO2 measurement caused the restart of the ventilation unit. Devices without integrated or with disabled CO2 measurement function are not affected. The behavior can be effectively prevented by not activating the integrated CO2 measurement. If necessary, external CO2 monitoring can be used. If the information from this safety notice is considered, the devices can remain in operation.

As of the date of this letter, 23 complaints for Evita V500 and Evita V300 had been reported worldwide to Dräger in relation to this behavior (which is a rate* of 3 within one year of operation of 1000 ventilators). There were no reports of any adverse impact on the health of the patients in question.

Drägerwerk AG & Co. KGaA
Moislinger Allee 53-55
23558 Lübeck, Deutschland
Postanschrift:
23542 Lübeck, Deutschland
Tel. +49 451 882-0
Fax +49 451 882-2080
info@draeger.com
www.draeger.com
UID-Nr. DE135082211

Bankverbindungen:
Commerzbank AG, Lübeck
IBAN: DE95 2304 0022 0014 6795 00
Swift-Code: COBA DE FF 230
Sparkasse zu Lübeck
IBAN: DE15 2305 0101 0001 0711 17
Swift-Code: NOLADE21SPL

Sitz der Gesellschaft: Lübeck
Handelsregister:
Amtsgericht Lübeck HRB 7903 HL
Komplementär: Drägerwerk Verwaltungs AG
Sitz der Gesellschaft: Lübeck
Handelsregister:
Amtsgericht Lübeck HRB 7395 HL

Vorsitzender des Aufsichtsrats der
Drägerwerk AG & Co. KGaA und
Drägerwerk Verwaltungs AG:
Stefan Lauer
Vorstand:
Stefan Dräger (Vorsitzender)
Rainer Klug
Gert-Hartwig Lescow
Dr. Reiner Piske
Anton Schrofner

During the restart, the ventilation is temporarily interrupted, and an audible alarm is activated by the auxiliary acoustic alarm system. The breathing system is opened to the ambient air during the restart to potentially allow the patient to breathe spontaneously. Opening the breathing system to ambient causes a loss of ventilation support from the ventilator including PEEP. The ventilation unit is restarted and after approximately 8 seconds automatically resumes ventilation at the identical settings prior to the restart. Once the restart process has been completed, the user is alerted to the fact by the alarm notification "Ventilation unit restarted" visually on the display unit, together with a sequence of audible alarm tones. Thereafter, the audible auxiliary acoustic alarm of the ventilation unit stops. Please refer to the Instructions for Use of the devices for further information about this alarm notification.

The release of a corrected software is expected to be available in Q4 of 2021. Once the software is available, your local Dräger Service representative or our service partner will contact you to arrange a date for the software update to be performed free of charge.

Please ensure that all users of the above-mentioned products and other concerned persons within your organization are made aware of this Important Safety Notice. If you have provided the products to third parties, please forward a copy of this information. Please keep this information at least until the corrective measure has been completed.

The responsible authorities have been notified of this action.

We apologize for any inconvenience but believe this to be an essential preventive measure to increase patient safety. We thank you for your support.



Frank Ralts
Senior Product Manager
Business Area Respiratory Care
Business Unit Therapy
Drägerwerk AG & Co. KGaA



Oliver Möller
Post Market Surveillance
Quality & Regulatory Affairs
Medical Division
Drägerwerk AG & Co. KGaA

*: rate calculation is based on number of reported events, installed base of devices and duration of operation, at the time of assessment